Alnylam Pharmaceuticals
ALNY
#1066
Rank
C$30.87 B
Marketcap
C$230.55
Share price
-5.17%
Change (1 day)
-63.32%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$7.71

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$7.73. In 2025 the company made an earnings per share (EPS) of C$2.88.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$7.71167.92%
2025C$2.88
2023C-$4.93-62%
2022C-$12.9829.03%
2021C-$10.06-3.36%
2020C-$10.41-8.48%
2019C-$11.377.67%
2018C-$10.5639.74%
2017C-$7.5612.94%
2016C-$6.6938.84%
2015C-$4.82-32.88%
2014C-$7.18259.44%
2013C-$2.00-31.25%
2012C-$2.91

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$9.31 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$2.66-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$58.56 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$3.67-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.02-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.13-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$0.88-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C-$4.65-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA